The goal is to understand why inflammatory signaling is elevated and whether modifiable drivers are present: visceral fat, periodontal disease, poor sleep, alcohol, insulin resistance, autoimmune activity, environmental exposure, chronic infection, or unresolved cardiometabolic risk
Feel better dailyfor as little as $1.66/day with a subscription
Many patients will start out taking semaglutide, and then later switch to tirzepatide when the semaglutide is no longer effective
doi: 10.3803/EnM.2021.102 Summary Keywords GLP-1 receptor agonists, endocrine, cardiovascular, neurological, cancer Citation Zhao X, Wang M, Wen Z, Lu Z, Cui L, Fu C, Xue H, Liu Y and Zhang Y (2021) GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects
target body fat percentage Compatibility with other treatments (IV vitamins, biostimulation, etc.) Key Stat: Clinical studies show Tirzepatide may lead to up to 22.5% weight loss vs
Recently, researchers have started studying the role of the GLP-1 receptors in cartilage cells, though more research is needed
